ChemoCentryx

HomepageEddy Mejia2020-06-16T19:00:14+00:00

A New Approach. A Better Approach.

LEARN MORE ABOUT OUR SCIENCE

PRODUCTS and PATIENTS

People Deserve Better Medicine

SHARE OUR PASSION

MEDICINE and LIFE

Not Just a Longer Life, a Better Life.

A New Approach. A Better Approach.

LEARN MORE ABOUT OUR SCIENCE

People Deserve Better Medicine

SHARE OUR PASSION

Not Just a Longer Life, a Better Life.

Positive topline data from pivotal Phase III ADVOCATE trial demonstrates avacopan’s superiority over standard of care in ANCA-associated vasculitis.

Learn about ACCOLADE, a clinical research study for people with C3 glomerulopathy.

RECENT NEWS:

NOW ENROLLING:

.A Phase 3 clinical trial to evaluate the safety and efficacy of avacopan in patients with ANCA-vasculitis »

Clinical study evaluating CCX140 in Focal Segmental Glomerulosclerosis (FSGS) with and without Nephrotic Syndrome – Now Enrolling.

RECENT NEWS:

ChemoCentryx to Present at Three Upcoming Investor Conferences »

People Deserve Better Medicine

At ChemoCentryx, we believe our patients deserve more than the standard of care available today. So, we are developing our broad portfolio of new medicines using a novel approach to better provide patients with safe, convenient and more effective therapies.

We are developing tomorrow’s standard of care.

Not Just a Longer Life, a Better Life

People suffering from serious medical conditions want more than incremental improvements. Like all of us, they want to live longer, more enjoyable lives. That’s why when others say, “This is the best we can do,” we say, “We can do better.”

We are developing a better way to treat disease.

Share our passion

A New Approach. A Better Approach.

Our vision is simple. We believe that a targeted biological system—the chemoattractant network—is the key to longer, better lives for thousands of people suffering from serious disease. And we intend to deliver that quality of life to patients through a passion for great science.

Our great science leads to great medicine.